SGLT-2 inhibitors have been clearly shown in multiple studies to improve renal outcomes in patients with CKD or DKD (Table 4), and glomerular hemodynamic function, significantly reduces the risk of proteinuria and renal failure [5, 78, 82, 84–86]. This evidence concerns the gene SLC5A2 and kidney failure.